Stockreport

KalVista Pharmaceuticals Provides Development Update and 2019 Clinical Plans

KalVista Pharmaceuticals, Inc.  (KALV) 
Last kalvista pharmaceuticals, inc. earnings: 3/10 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.kalvista.com
PDF – KVD900 Phase 2 HAE Trial Data Expected in 2019 – – KVD824 Named as Next Oral Plasma Kallikrein Inhibitor to Enter Clinic – CAMBRIDGE [Read more]